



Claus Garbe

Contact

Claus Garbe

Publications (27)

Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. *J Am Acad Dermatol* 2023

Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. *Eur J Cancer* 2023; 196:113425.

Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. *J Am Acad Dermatol* 2023; 89:1072-1074.

Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. *Pigment Cell Melanoma Res* 2023; 36:512-521.

Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. *EBioMedicine* 2023; 93:104644.

Gaessler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. *J Immunother Cancer* 2023; 11

Gaessler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. *Front Immunol* 2022; 13:906352.

Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol* 2022; 40:3741-3749.

Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. *J Cancer Res Clin Oncol* 2022; 149:833-840.

Serna-Higuita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. *Cancers (Basel)* 2021; 13

Keim U, Gandini S, Amaral T, Katalinic A, Holleccek B, Flatz L, Leiter U, Whiteman D, Garbe C. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. *Eur J Cancer* 2021; 159:98-104.

Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi A, Keim U, Garbe C, Wagner N, Forchhammer S. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. *Cancers (Basel)* 2021; 13

Garbe C, Leiter U, Flatz L, Martus P, Holleccek B, Katalinic A, Amaral T, Gandini S, Keim U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. *Eur J Cancer* 2021; 152:18-25.

Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. *Target Oncol* 2021; 16:197-205.

Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer* 2021; 9

Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. *J Immunother Cancer* 2021; 9

Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. *Cancer Immunol Immunother* 2020; 70:1089-1099.

Gassenmaier M, Garbe C, Schaller M, Wagner N, Bösmüller H, Niessner H, Sinnberg T, Kosnopfel C, Ikenberg K, Eigentler T, Fehrenbacher B, Rentschler M, Röcken M. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. *Am J Pathol* 2020; 190:2155-2164.

Wagner N, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler T. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. *Australas J Dermatol* 2020; 61:e310-e318.

Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. *J Immunother Cancer* 2019; 7:343.

Bochem J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. *PLoS one* 2019; 14:e0221301.

Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. *Br J Cancer* 2018; 119:339-346.

Gassenmaier M, Garbe C, Eigentler T, Doecker D, Mueller A, Kofler L, Wagner N, Scheu A, Lipp H, Forschner A. Safety of shortened infusion times for combined ipilimumab and nivolumab. *Cancer Immunol Immunother* 2017; 67:135-140.

Wagner N, Utikal J, Enk A, Umansky V, Garbe C, Naeher H, Holland-Letz T, Busch C, Ikenberg K, Eubel J, Herpel E, Pflugfelder A, Lichtenberger R, Kehrel C, Tarnanidis K, Reith M, Weide B, Gebhardt C. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. *Int J Cancer* 2015; 137:2607-17.

Mehra T, Naumann A, Clasen S, Dummer R, Claussen C, Röcken M, Moos R, Guenova E, Mann S, Grözinger G, Garbe C. Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. *PloS one* 2014; 9:e112535.

Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppli M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. *PloS one* 2013; 8:e53745.

Meier F, Garbe C, Knaudt B, Zielinski C, Leiter U, Forschner A, Eigentler T, Clasen S, Guenova E, Berneburg M. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. *J Am Acad Dermatol* 2009; 60:863-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch